$7.08
-0.16[-2.21%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$7.08
0[0.00%]
| Open7.300 | Close7.080 |
| Vol / Avg.1.289M / 2.519M | Mkt Cap1.342B |
| Day Range7.040 - 7.341 | 52 Wk Range6.620 - 14.500 |
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%
BioCryst Pharma Stock (NASDAQ:BCRX), Key Statistics
BioCryst Pharma Stock (NASDAQ: BCRX) analysis, key statistics.
Valuation Measures
Enterprise Value
1.8B
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
4.43
Price / Book (mrq)
- -
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-17.82%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
-2.05
Tangible Book value per share
-2.05
Total Liabilities (Quarterly)
918.6M
Total Assets
529.9M
Total Liabilities
- -
Profitability
Net income Growth
- -
Gross Margin
98.85%
Net Margin
-91.31%
EBIT Margin
-55.36%
EBITDA Margin
-54.87%
Operating Margin
-25.1%